FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954998037> ?p ?o ?g. }

• W2954998037 endingPage "3384" @default.
• W2954998037 startingPage "3373" @default.
• W2954998037 abstract "// Florentia Dimitriou 1 , Joanna Mangana 1 , Alessandra Curioni-Fontecedro 2 , 4 , Markus Rechsteiner 3 , Patrick Turko 1 , Ralph P. Braun 1 , 4 , Reinhard Dummer 1 , 4 , * and Phil F. Cheng 1 , * 1 Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland 2 Department of Hematology and Oncology, Division of Oncology, University Hospital of Zurich, Zurich, Switzerland 3 Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland 4 Faculty of Medicine, University of Zurich, Zurich, Switzerland * These authors contributed equally to this work Correspondence to: Reinhard Dummer, email: reinhard.dummer@usz.ch Phil F. Cheng, email: phil.cheng@usz.ch Keywords: melanoma; additional primary tumors; multiple primary tumors; BRAF V600E mutation; papillary thyroid cancer Received: March 28, 2019     Accepted: April 29, 2019     Published: May 21, 2019 ABSTRACT Background: Recent progress in the diagnosis and treatment of primary and metastatic cutaneous melanoma (CM) has led to a significant increase in the patients` expectancy of life. The development of additional primary tumors (APT) other than CM represents an important survival issue. Results: Of a total of 1764 CM patients, 80 (4.5%) patients developed APT. For tumors diagnosed after CM, there was a 2.7 fold excess risk for APT compared to the swiss german population. A significantly increased risk was noted for female breast (SIR, 2.46), male larynx (SIR, 76.92), male multiple myeloma (SIR, 11.2), male oesophagus (SIR, 10.8) and thyroid on males (SIR, 58.8) and females (SIR, 38.1). All thyroid cancer cases had a common papillary histological subtype and a high rate of BRAFV600E mutation. Melanoma was the primary cause of death in the vast majority of patients. Methods: We used the cancer registry from the Comprehensive Cancer Center Zurich (CCCZ) and retrospectively analyzed patients with CM and APT between 2008 and 2018. We calculated the risk of APT compared to the swiss german population using the standardized incidence ratio (SIR). Conclusions: Patients with CM have an increased risk for hematologic and solid APT. Long-term follow-up is indicated." @default.
• W2954998037 created "2019-07-12" @default.
• W2954998037 creator A5008364803 @default.
• W2954998037 creator A5033515147 @default.
• W2954998037 creator A5038532092 @default.
• W2954998037 creator A5039101695 @default.
• W2954998037 creator A5046436556 @default.
• W2954998037 creator A5059011363 @default.
• W2954998037 creator A5082278497 @default.
• W2954998037 creator A5089297467 @default.
• W2954998037 date "2019-05-21" @default.
• W2954998037 modified "2023-10-16" @default.
• W2954998037 title "Melanoma patients with additional primary cancers: a single-center retrospective analysis" @default.
• W2954998037 cites W1486574296 @default.
• W2954998037 cites W1603524108 @default.
• W2954998037 cites W1950829641 @default.
• W2954998037 cites W1980958967 @default.
• W2954998037 cites W1994616051 @default.
• W2954998037 cites W1998557711 @default.
• W2954998037 cites W2004042654 @default.
• W2954998037 cites W2007569529 @default.
• W2954998037 cites W2016568498 @default.
• W2954998037 cites W2023568503 @default.
• W2954998037 cites W2025108097 @default.
• W2954998037 cites W2042067040 @default.
• W2954998037 cites W2044433401 @default.
• W2954998037 cites W2049982157 @default.
• W2954998037 cites W2051978744 @default.
• W2954998037 cites W2076055196 @default.
• W2954998037 cites W2086535578 @default.
• W2954998037 cites W2089415609 @default.
• W2954998037 cites W2094094629 @default.
• W2954998037 cites W2096322385 @default.
• W2954998037 cites W2103496385 @default.
• W2954998037 cites W2118986295 @default.
• W2954998037 cites W2127630510 @default.
• W2954998037 cites W2133282020 @default.
• W2954998037 cites W2161951166 @default.
• W2954998037 cites W2163188200 @default.
• W2954998037 cites W2284583894 @default.
• W2954998037 cites W2335844855 @default.
• W2954998037 cites W2423290579 @default.
• W2954998037 cites W2489579353 @default.
• W2954998037 cites W2509603974 @default.
• W2954998037 cites W2560367415 @default.
• W2954998037 cites W2593526662 @default.
• W2954998037 cites W2605233023 @default.
• W2954998037 cites W2655723508 @default.
• W2954998037 cites W2746148521 @default.
• W2954998037 cites W2749309167 @default.
• W2954998037 cites W2759130309 @default.
• W2954998037 cites W2770511030 @default.
• W2954998037 cites W2781525129 @default.
• W2954998037 cites W2787607544 @default.
• W2954998037 cites W2791963585 @default.
• W2954998037 cites W2801375248 @default.
• W2954998037 cites W2884102988 @default.
• W2954998037 doi "https://doi.org/10.18632/oncotarget.26931" @default.
• W2954998037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6534365" @default.
• W2954998037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31164959" @default.
• W2954998037 hasPublicationYear "2019" @default.
• W2954998037 type Work @default.
• W2954998037 sameAs 2954998037 @default.
• W2954998037 citedByCount "5" @default.
• W2954998037 countsByYear W29549980372021 @default.
• W2954998037 countsByYear W29549980372022 @default.
• W2954998037 countsByYear W29549980372023 @default.
• W2954998037 crossrefType "journal-article" @default.
• W2954998037 hasAuthorship W2954998037A5008364803 @default.
• W2954998037 hasAuthorship W2954998037A5033515147 @default.
• W2954998037 hasAuthorship W2954998037A5038532092 @default.
• W2954998037 hasAuthorship W2954998037A5039101695 @default.
• W2954998037 hasAuthorship W2954998037A5046436556 @default.
• W2954998037 hasAuthorship W2954998037A5059011363 @default.
• W2954998037 hasAuthorship W2954998037A5082278497 @default.
• W2954998037 hasAuthorship W2954998037A5089297467 @default.
• W2954998037 hasBestOaLocation W29549980371 @default.
• W2954998037 hasConcept C121608353 @default.
• W2954998037 hasConcept C126322002 @default.
• W2954998037 hasConcept C143998085 @default.
• W2954998037 hasConcept C2777658100 @default.
• W2954998037 hasConcept C2779761222 @default.
• W2954998037 hasConcept C2908647359 @default.
• W2954998037 hasConcept C502942594 @default.
• W2954998037 hasConcept C530470458 @default.
• W2954998037 hasConcept C71924100 @default.
• W2954998037 hasConcept C99454951 @default.
• W2954998037 hasConceptScore W2954998037C121608353 @default.
• W2954998037 hasConceptScore W2954998037C126322002 @default.
• W2954998037 hasConceptScore W2954998037C143998085 @default.
• W2954998037 hasConceptScore W2954998037C2777658100 @default.
• W2954998037 hasConceptScore W2954998037C2779761222 @default.
• W2954998037 hasConceptScore W2954998037C2908647359 @default.
• W2954998037 hasConceptScore W2954998037C502942594 @default.
• W2954998037 hasConceptScore W2954998037C530470458 @default.
• W2954998037 hasConceptScore W2954998037C71924100 @default.
• W2954998037 hasConceptScore W2954998037C99454951 @default.
• W2954998037 hasIssue "36" @default.

• next